Related Experiment Video
Updated: Jul 12, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
[Extracellular vesicle-mediated drug resistance in multiple myeloma]
Tomofumi Yamamoto1,2, Yusuke Yamamoto1
1Laboratory of Integrative Oncology, National Cancer Center Research Institute.
Abstract:
Because of innovative therapeutic agents such as proteasome inhibitors, immunomodulatory medicines, and antibody medications, the prognosis of multiple myeloma (MM) has considerably improved in recent years. However, the prognosis for MM patients with treatment resistance and extramedullary illness remains poor. The interaction between MM cells and their surrounding cells in the bone marrow microenvironment is critical for medication resistance development. Many issues cannot be explained by liquid factors, such as cytokines and chemokines. Extracellular vesicles (EVs) have gained interest due to their role in the advancement of several forms of cancers. In this article, we primarily summarize MM drug resistance and examine the most recent articles on small-EVs (particularly exosomes) that contribute to MM drug resistance acquisition.
Insights
Innovative treatments have improved multiple myeloma (MM) outcomes, but drug resistance persists. Small extracellular vesicles (EVs), particularly exosomes, are increasingly recognized for their role in mediating MM drug resistance.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Related Concept Videos
Treatment Resistant Cancers
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Intralumenal Vesicles and Multivesicular Bodies

